LYNPARZA

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug LYNPARZA contains one active pharmaceutical ingredient (API):

1 Olaparib UNII WOH1JD9AR8 - OLAPARIB

Olaparib is a potent inhibitor of human poly (ADP-ribose) polymerase enzymes (PARP-1, PARP-2, and PARP-3), and has been shown to inhibit the growth of selected tumour cell lines in vitro and tumour growth in vivo either as a standalone treatment or in combination with established chemotherapies or new hormonal agents (NHA). Read about Olaparib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LYNPARZA Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC
LYNPARZA Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XK01		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors
Discover more medicines within L01XK01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11050N, 11503K, 11522K, 11528R, 11539H, 12157W, 12161C, 12169L, 12170M
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 502317050031101, 502319020033801, 502319020033901
Country: CA	Health Products and Food Branch	Identifier(s): 02454408, 02475200, 02475219
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 2125-MEE-0516, 5534-MEE-1020, 5661-MEE-1120
Country: EE	Ravimiamet	Identifier(s): 1673995, 1771196, 1771208, 1771219, 1771220, 1797925
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 114959001, 114959002, 114959004
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 172731, 412504, 567228
Country: FR	Base de données publique des médicaments	Identifier(s): 60058620, 64748533, 65789903
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 297475, 354988, 354991, 392406, 392408
Country: HK	Department of Health Drug Office	Identifier(s): 64538, 65987, 65988
Country: IE	Health Products Regulatory Authority	Identifier(s): 88871, 89038, 89039
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8453, 8454
Country: IT	Agenzia del Farmaco	Identifier(s): 043794015, 043794027, 043794039, 043794041, 043794054
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291052F1027, 4291052F2023
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1075368, 1085848, 1085849, 1085850, 1085851
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 122947, 150959, 150967
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 18278, 19610, 19611
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100334749, 100405930, 100405946
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W61522002, W64660001, W64661001
Country: SG	Health Sciences Authority	Identifier(s): 15025P, 15662P, 15663P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699786092907, 8699786092914, 8699786092921, 8699786092938
Country: US	FDA, National Drug Code	Identifier(s): 0310-0668, 0310-0679